IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

CENTRAL FAX CENTER

Applicants

: Lundberg et al.

Serial No.

: 09/646,852

FEB 0 6 2006

Filing or 371(c) Date

: September 22, 2000

For

: NEW FORMULATION

Examiner

: Tran, Susan T.

Group Art Unit

: 1615

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 571-273-8300.

John M. Genova

Agent Name

PTO Reg. No.

Signature

Date of Signature

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

ATTENTION: Examiner Susan T. Tran

DATE: 6 February 2006 NUMBER OF PAGES: 22

FAX NUMBER: 571-273-8300

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. §1.97(c))

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Except for the U.S. parents and published patent application, a copy of each of the documents cited on the attached forms PTO/SB/08A is enclosed.

02/07/2006 HDEMESS1 00000057 231703 09646852

01 FC:1806

180.00 DA

Time Of Transmittal Of Information Disclosure Statement

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the entry of the national stage as set forth in §1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last but before the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311, whichever occurs first.

Copies of Cited U.S. Patent Documents are Not Provided

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Forms PTO/SB/08A are not provided with this Information Disclosure Statement.

Statement Or Fee

Accompanying this Information Disclosure Statement is

A.

a statement as specified in 37 C.F.R. §1.97 (e).

OR

B. the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00).

Fee Payment

Applicants elect the option to pay the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under §1.197(c) (\$180.00).

Fee due \$ 180.00

Method Of Payment Of Fee

☐ Attached is a check in the amount of \$ _____.

⊠ Charge Account No. 23-1703 in the amount of \$180.00

If any additional fees are due, please charge Account No. 23-1703.

Dated: 6 February 2006

Respectfully submitted,

John M. Genova Reg. No. 32,224

Customer No. 007470 White & Casc LLP

Attorney Direct Dial: (212) 819-8832

1103326-0636

PTU/SFI/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trudemerk Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information usless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
Suostitute	i for form 144WPTO			Application Number	USSN 09/646,852	
INTEGRAL TION DISCUSSION			LOCIDE	Filing Date	September 22, 2000	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Per Johan Lundberg et al.	
				Art Unit	1615	
				Examiner Name	Suşan T. Tran	
Sheet	1		1	Attorney Docket Number	1103326-0636	

Examiner	Cite	Document Number	TENT DOCUMEN Publication Date	Name of Patentee	Pages, Columns, Lines, Where
Initials*	No.'	Number-Kind Code ² (d human)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages/Figures Appear
	1				
			ļ		ļ
	1				
	+				
	+			 	
	1	,	<u> </u>		
		FOREIGN 1	PATENT DOCUM		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ⁵	Publication Date	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear
		(if known)	MM-DD-YYYY		
	<u> </u>				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTE	ITERATURE DO	hen appropriate), title of the	item (book, magazine, journal, pountry where published.
			IRS), title of the article (w ge(s), volume-issue numbe	then appropriate), title of the er(s), publisher, city and/or o	ountry where published.
		Include name of the author (in CAPITAL LETTE scrial, symposium, catalog, etc.), date, pag Hengels, K.J., "Aus der Medizinischen K	RS), title of the article (w ge(s), volume-issue numb Llinik D der Universiti ulfonyl)benzimidazole	when appropriate), title of the er(s), publisher, city and/or c et Düsseldorf*, Z. Gastr es: Acid Sensitive Suici	oenterologie 22 (1984) de Inhibitors of the Proton
		Include name of the author (in CAPITAL LETTE scrial, symposium, catalog, etc.), date, pag Hengels, K.J., "Aus der Medizinischen K pp. 241-243. Rackur, G. et al., "2-((2-pyridylmethyl)st Transport System", Biochemical and Bio	RS), title of the article (w. e(s), volume-issue number linik D der Universitätliche (m. etc.) benzimidazole physical Research Cogastric proton pump i	then appropriate), title of the r(s), publisher, city and/or city and city	de Inhibitors of the Proton 8, No. 1 (1985), pp. 477-
		Include name of the author (in CAPITAL LETTE scrial, symposium, catalog, etc.), date, pag Hengels, K.J., "Aus der Medizinischen K pp. 241-243. Rackur, G. et al., "2-((2-pyridylmethyl)st Transport System", Biochemical and Bio 484. Lind, T. et al., "Effect of omeprazole – a	RS), title of the article (w. e(s), volume-issue number linik D der Universitätliche (m. etc.) benzimidazole physical Research Cogastric proton pump i	then appropriate), title of the r(s), publisher, city and/or city and city	de Inhibitors of the Proton 8, No. 1 (1985), pp. 477-
		Include name of the author (in CAPITAL LETTE scrial, symposium, catalog, etc.), date, pag Hengels, K.J., "Aus der Medizinischen K pp. 241-243. Rackur, G. et al., "2-((2-pyridylmethyl)st Transport System", Biochemical and Bio 484. Lind, T. et al., "Effect of omeprazole – a	RS), title of the article (w. e(s), volume-issue number linik D der Universitätliche (m. etc.) benzimidazole physical Research Cogastric proton pump i	then appropriate), title of the r(s), publisher, city and/or city and city	de Inhibitors of the Proton 8, No. 1 (1985), pp. 477-
	No.	Include name of the author (in CAPITAL LETTE scrial, symposium, catalog, etc.), date, pag Hengels, K.J., "Aus der Medizinischen K pp. 241-243. Rackur, G. et al., "2-((2-pyridylmethyl)st Transport System", Biochemical and Bio 484. Lind, T. et al., "Effect of omeprazole – a	RS), title of the article (w. e(s), volume-issue number linik D der Universitätliche (m. etc.) benzimidazole physical Research Cogastric proton pump i	then appropriate), title of the r(s), publisher, city and/or city and city	de Inhibitors of the Proton 8, No. 1 (1985), pp. 477-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if on in conformance and not considered. Include copy of this flow with rest communication to applicant. Applicant's under condition designation number (optional). See Kinds Codes of UNFO Parent Documents as specification of the patient documents, the indication of the year of the reign of the Emperor unant proceds the reign and the patient documents. Nind of documents by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a chart has the reign Heights between Profiles that the process of information in required to 3 to 16 if possible. Applicant is to place a chart has the reign Heights between Profiles the Process of information in required to 17 if 17 possible. Applicant is to place a chart has about the Chart has the reign between Profiles between Profiles that the Chart has the reign between the profiles that the process of information is required to the proving the public which is to file (and by the USPTO to process) as application. Confidentiality is governed by 35 U.S.C. (23 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, propulse, and submitting the completed applications form to the USPTO. These wall very depending each the Individual case. Any comments on the sweet of time you require to make a produce and produce